- Email: [email protected]
Reply to Dr. Benson
Volume Number
132 6
ing tracings for the OCT be made at 3 cm. per minute for more accurate analysis. LeRoy J. Dierker, Jr., M.D. Depatirnertt of Obstetrics and Gynecology Cleveland Metropolitan General Hospital Case Western Reserve University Cleveland, Ohio 44109 To the Editors: Two cases were cited in the article by Drs. Salerno and Kay in which fetal compromise occurred within a week of a negative OCT. They presented a tracing of an OCT done January 21 on Case 2 and read as negative. When repeated because of falling estriol values on January 25, the interpretation was then positive. A cesarean section was performed with the statement being made that “a decrease in interval between OCT’s saved the fetus.” I submit that a close examination of the tracing interpreted as a negative OCT reveals it to be a suggestive or equivocal OCT, as defined by Trierweiler and associates,’ and it should have been repeated in 24 hours. Another fact to consider is that this tracing appears much different than the subsequent positive OCT because the former was done at 2 cm. per minute while the latter was at 1 cm. per minute. I believe that one must adhere to the standard criteria for interpreting results before making an attempt to challenge a technique that has proved beneficial in obstetrics. Louis Weinstein, M.D. Department of Obstetrics and Gynecology Health Sciences Center The Lrniversity of Arizona 1501 N. Campbell Avenue Tucson, Arizona 85724 REFERENCE
Trierweiler,
M. W., Freeman, R. K., and James, J.: Baseline fetal heart rate characteristics as an indicator of fetal status during the antepartum period, AM. J. OBSTET. GYNECOL. 125: 618, 1976.
Reply to Drs. Dierker and Weinstein To the Editors: Drs. Dierker and Weinstein are both perfectly correct in their interpretation of Fig. 2. On review this tracing was found to be suspicious. We wish to thank both physicians for calling this to our attention and the recommendation of both to standardize paper speeds is an excellent one. Nicholas J. Salerno, M.D. T. R. Kay, M.D. Department of Obstetrics and Gynecology Garden State Community Hospital Marlton, New Jersey 08053
Correspondence
703
Progestasert* system To the Editors: We read with interest the article by Ylikorkala and Dawood, “New concepts in dysmenorrhea,” AM. J. OBSTET. GYNECOL. 130: 833, 1978. The article refers to one of our products, the Progestasert intrauterine progesterone contraceptive system. An error appears on page 844 under “Locally administered medications.” The footnote at the end of the paragraph indicates that Ciba-Geigy, Basel, Switzerland, is the manufacturer of the Progestasert system; actually, the manufacturer of Progestasert is Alza Corporation, Palo Alto, California. The confusion is probably due to recent agreements signed by Alza and Ciba-Geigy, in which Ciba-Geigy has voting control of Alza. Although these agreements give Ciba-Geigy the option to market and manufacture the product in the future, Alza remains an independent company and is responsible for both manufacturing and marketing the Progestasert system at present. Harriet Benson, Ph.D. Area Director Literature Research Alza Corporation 950 Page Mill Road Palo Alto, California 94304 *Progestasert
is a registered
trademark
of Alza Cor-
poration.
Reply to Dr. Benson To the Editors: We thank Dr. Harriet Benson for her interest on our article, and for pointing out that Progestasert is manufactured by Alza Corporation of Palo Alto, California. In the manuscript that we submitted we had not put the name of any manufacturer, but the name of CibaGeigy, Basel, Switzerland, appeared in the published COPY.
M. YusoffDawood, M.D. Department of Obstetrics and Gynecology The New York Hospital-Cornell Medical Center 525 East 68th Street New York, New York 10021 Olavi Ylikorkala, M.D. Department of Obstetrics and Gynecology University of Oulu Oulu, Finland
Single-dose metronidazole To the Editors: Single-dose metronidazole has been used for the treatment of trichomonal vaginitis in a series of 159 patients since April 14, 1974. The first 51 patients were
132 6
ing tracings for the OCT be made at 3 cm. per minute for more accurate analysis. LeRoy J. Dierker, Jr., M.D. Depatirnertt of Obstetrics and Gynecology Cleveland Metropolitan General Hospital Case Western Reserve University Cleveland, Ohio 44109 To the Editors: Two cases were cited in the article by Drs. Salerno and Kay in which fetal compromise occurred within a week of a negative OCT. They presented a tracing of an OCT done January 21 on Case 2 and read as negative. When repeated because of falling estriol values on January 25, the interpretation was then positive. A cesarean section was performed with the statement being made that “a decrease in interval between OCT’s saved the fetus.” I submit that a close examination of the tracing interpreted as a negative OCT reveals it to be a suggestive or equivocal OCT, as defined by Trierweiler and associates,’ and it should have been repeated in 24 hours. Another fact to consider is that this tracing appears much different than the subsequent positive OCT because the former was done at 2 cm. per minute while the latter was at 1 cm. per minute. I believe that one must adhere to the standard criteria for interpreting results before making an attempt to challenge a technique that has proved beneficial in obstetrics. Louis Weinstein, M.D. Department of Obstetrics and Gynecology Health Sciences Center The Lrniversity of Arizona 1501 N. Campbell Avenue Tucson, Arizona 85724 REFERENCE
Trierweiler,
M. W., Freeman, R. K., and James, J.: Baseline fetal heart rate characteristics as an indicator of fetal status during the antepartum period, AM. J. OBSTET. GYNECOL. 125: 618, 1976.
Reply to Drs. Dierker and Weinstein To the Editors: Drs. Dierker and Weinstein are both perfectly correct in their interpretation of Fig. 2. On review this tracing was found to be suspicious. We wish to thank both physicians for calling this to our attention and the recommendation of both to standardize paper speeds is an excellent one. Nicholas J. Salerno, M.D. T. R. Kay, M.D. Department of Obstetrics and Gynecology Garden State Community Hospital Marlton, New Jersey 08053
Correspondence
703
Progestasert* system To the Editors: We read with interest the article by Ylikorkala and Dawood, “New concepts in dysmenorrhea,” AM. J. OBSTET. GYNECOL. 130: 833, 1978. The article refers to one of our products, the Progestasert intrauterine progesterone contraceptive system. An error appears on page 844 under “Locally administered medications.” The footnote at the end of the paragraph indicates that Ciba-Geigy, Basel, Switzerland, is the manufacturer of the Progestasert system; actually, the manufacturer of Progestasert is Alza Corporation, Palo Alto, California. The confusion is probably due to recent agreements signed by Alza and Ciba-Geigy, in which Ciba-Geigy has voting control of Alza. Although these agreements give Ciba-Geigy the option to market and manufacture the product in the future, Alza remains an independent company and is responsible for both manufacturing and marketing the Progestasert system at present. Harriet Benson, Ph.D. Area Director Literature Research Alza Corporation 950 Page Mill Road Palo Alto, California 94304 *Progestasert
is a registered
trademark
of Alza Cor-
poration.
Reply to Dr. Benson To the Editors: We thank Dr. Harriet Benson for her interest on our article, and for pointing out that Progestasert is manufactured by Alza Corporation of Palo Alto, California. In the manuscript that we submitted we had not put the name of any manufacturer, but the name of CibaGeigy, Basel, Switzerland, appeared in the published COPY.
M. YusoffDawood, M.D. Department of Obstetrics and Gynecology The New York Hospital-Cornell Medical Center 525 East 68th Street New York, New York 10021 Olavi Ylikorkala, M.D. Department of Obstetrics and Gynecology University of Oulu Oulu, Finland
Single-dose metronidazole To the Editors: Single-dose metronidazole has been used for the treatment of trichomonal vaginitis in a series of 159 patients since April 14, 1974. The first 51 patients were